contesting it, and the proposed amendment to the record.

RECORD SOURCE CATEGORIES:

Individuals or entities having information pertinent to the adjudication of compensation claims, including but not limited to: Injured individuals; personal representatives of deceased individuals; eligible claimants; family members; physicians and other medical professionals, hospitals, and clinics; insurers, employers, and their agents and representatives.

SYSTEMS EXEMPTED FROM CERTAIN PROVISIONS OF THE ACT:

None.

[FR Doc. 01–31461 Filed 12–18–01; 12:28 pm]

BILLING CODE 4410–12–P

DEPARTMENT OF JUSTICE

Antitrust Division

United States v. Premdor Inc. et al.

A Complaint, Hold Separate Stipulation and Order, proposed Final Judgment, and Competitive Impact Statement were filed with the United States District Court for the District of Columbia, in a civil antitrust case, *United States* v. *Premdor Inc., Premdor U.S. Holdings, Inc., International Paper Company, and Masonite Corporation,* Civ. Action No. 1:01CV01696. By August 28, 2001, the United States published a notice in the Washington Post and the **Federal Register,** seeking public comments on the proposed settlement, in accord with the Antitrust Procedures and Penalties Act, 15 U.S.C. 16(b) through (h). The 60 day comment period expired on October 29, 2001. Due to the unanticipated disruption of mail service to the U.S. Department of Justice, the United States requests that anyone who submitted a comment before the expiration of the comment period resubmit the comment by facsimile or e-mail to J. Robert Kramer II, Chief, Litigation II Section, Antitrust Division, U.S. Department of Justice, 1401 H Street, NW., Suite 3000, Washington, DC 20530 (facsimile: (202) 307–5802; e-mail: *comments.lit2@usdoj.gov;* telephone: (202) 307–0924). Comments should be resubmitted by facsimile or e-mail within 15 days of the date of this notice.

Constance K. Robinson,

Director of Operations & Merger Enforcement.

[FR Doc. 01–31477 Filed 12–20–01; 8:45 am]

BILLING CODE 4410–11–M

DEPARTMENT OF JUSTICE

Antitrust Division

United States v. 3d Systems Corp. and DTM Corp.

A Complaint, proposed Final Judgment, and Competitive Impact Statement were filed with the United States District Court for the District of Columbia, in a civil antitrust case, *United States* v. *3D Systems Corporation and DTM Corporation*, Civ. Action No. 1:01CV01237. By September 26, 2001, the United States published a notice in the Washington Post and the **Federal Register**, seeking public comments on the proposed settlement, in accord with the Antitrust Procedures and Penalties Act, 15 U.S.C. 16(b) through (h). The 60-day comment period expired on November 26, 2001. Due to the unanticipated disruption of mail service to the U.S. Department of Justice, the United States requests that anyone who submitted a comment before the expiration of the comment period resubmit the comment by facsimile or e-mail to J. Robert Kramer II, Chief, Litigation II Section, Antitrust Division, U.S. Department of Justice, 1401 H Street, NW., Suite 3000, Washington, DC 20530 (facsimile: (202) 307–5802; e-mail: *comments.lit2@usdoj.gov*; telephone: (202) 307–0924). Comments should be resubmitted by facsimile or e-mail within 15 days of the date of this notice.

Constance K. Robinson,

Director of Operations & Merger Enforcement.

[FR Doc. 01–31478 Filed 12–20–01; 8:45 am]

BILLING CODE 4410–11–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 8, 2001, American Radiolabeled Chemical, Inc., 11624 Bowling Green Drive, St. Louis, Missouri 63146, made application by renewal and by letter dated May 2, 2001, to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Gamma hydroxybutyric acid (2010).	I
Lysergic acid diethylamide (7315)	I
Dimethyltryptamine (7435)	I
Dihydromophine (9145)	I
Phencyclidine (7471)	II
Cocaine (9041)	II
Codeine (9050)	II
Hydromorphone (9150)	II
Oxycodone (9143)	II
Thebaine (9333)	II
Benzoylecgonine (9180)	II
Meperidine (9230)	II
Metazocine (9240)	II
Morphine (9300)	II
Oxymorphone (9652)	II

The firm plans to bulk manufacture small quantities of the listed controlled substances as radiolabeled compounds.

Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than February 19, 2002.

Dated: November 15, 2001.

Laura M. Nagel,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 01–31408 Filed 12–20–01; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on September 11, 2001, Genesis 1:29 Corporation, P.O. Box 2175, 133 Bond Avenue, Petaluma, California 94654, made application to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basis classes of controlled substances listed below:

Drug	Schedule
Marihuana (7360)	I
Tetrahydrocannabinols (7370)	I

The firm plans to cultivate marihuana to supply physician's patients within the State of California.